Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

<p><strong>Background</strong> Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absenc...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Elsevier 2020

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Antzeko izenburuak